OMCLHealthcare · Health Information ServicesThe 8 Wall Street analysts covering Omnicell, Inc. hold a median 12-month price target of $60 — +64.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 12 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Omnicell, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (57): The shares have been drifting down relative to others.
Size (37): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OMCL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +64.6% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | Piper Sandler | Reiterates | Overweight | $55 → $45 |
| 31 July 2026 | Keybanc | Maintains | Overweight | $70 → $65 |
| 31 July 2026 | Wells Fargo | Maintains | Overweight | $55 → $50 |
| 29 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 29 Apr 2026 | Keybanc | Maintains | Overweight | $60 → $70 |
| 23 Apr 2026 | Wells Fargo | Maintains | Overweight | — |
| 23 Apr 2026 | Wells Fargo | Maintains | Overweight | $52 → $55 |
| 6 Feb 2026 | Piper Sandler | Reiterates | Overweight | — |
| 2 Feb 2026 | Benchmark | Maintains | Buy | — |
| 8 Jan 2026 | Keybanc | Upgrade | Overweight | — |
| 5 Jan 2026 | Wells Fargo | Maintains | Overweight | — |
| 9 Dec 2025 | B of A Securities | Maintains | Neutral | — |
| 9 Dec 2025 | Benchmark | Maintains | Buy | — |
| 31 Oct 2025 | Benchmark | Maintains | Buy | — |
| 11 Aug 2025 | Piper Sandler | Maintains | Overweight | — |
| 21 July 2025 | Wells Fargo | Maintains | Overweight | — |
| 14 July 2025 | B of A Securities | Maintains | Neutral | — |
| 23 May 2025 | B of A Securities | Maintains | Neutral | — |
| 23 May 2025 | Wells Fargo | Maintains | Overweight | — |
| 14 May 2025 | Wells Fargo | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OMCL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, Omnicell, Inc. returned +23.7% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 62% of US stocks
Cheaper than 63% of US stocks
Cheaper than 17% of US stocks
Higher than 45% of US stocks
Higher than 93% of US stocks
Higher than 61% of US stocks
Higher than 57% of US stocks
Higher than 56% of US stocks
Higher than 50% of US stocks
Higher than 55% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Omnicell, Inc. has a market value of $1.7B and an enterprise value of $1.6B.
Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 7.5% year on year.
Net income over the same four quarters: $39.1M, a 3.1% net margin.
Diluted earnings per share, trailing twelve months: $0.84.
Free cash flow in the twelve months to 30 June 2026: $126.8M.
Trailing P/E: 43.4×; forward P/E: 17.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Omnicell, Inc. employs 3,485 people — $358K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Omnicell, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Omnicell raised its 2026 earnings outlook, citing cost discipline and efficiency. Rising memory costs and delayed adoption of Titan XT remain challenges.
Why it matters — OMCL watchers may weigh the stronger outlook against the cost pressures and slower Titan XT adoption highlighted in the item.
Omnicell announced that it will release its third-quarter 2026 financial results on October 29, 2026.
Why it matters — OMCL watchers can note the scheduled date for the company’s third-quarter financial results.
Zacks Investment Research highlights Omnicell (OMCL) as a top-ranked value stock, pointing to its Style Scores system that helps investors identify strong, market-beating stocks for their portfolios.
Why it matters — A top-ranking from Zacks' value criteria may draw investor attention to Omnicell and reinforce its positioning among value-oriented stocks.
Zacks Investment Research highlighted Omnicell (OMCL) as a strong value stock using its Zacks Style Scores, which help investors identify strong, market-beating stocks for their portfolios. The article points to Omnicell's favorable value characteristics.
Why it matters — OMCL watchers would note that the stock has been flagged by Zacks' Style Scores as a strong value pick, which could attract additional investor attention.
TraceLink and Omnicell have integrated their DSCSA compliance solution into hospital pharmacy operations, bringing serialized product verification and traceability directly into medication receiving workflows. The integration is intended to enable more efficient pharmacy operations without requiring separate compliance processes.
Why it matters — OMCL watchers would care because this integration could streamline pharmacy compliance workflows and potentially strengthen Omnicell's product offering within hospital pharmacy operations.
The 8 Wall Street analysts covering Omnicell, Inc. have a median 12-month price target of $60, with estimates ranging from $45 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Omnicell, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omnicell, Inc. 97 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, Omnicell, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +64.6% from the last close, and Ticker Nerd's factor model ranks Omnicell, Inc. 97 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Omnicell, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMCL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $70 over the next 12 months.
Omnicell, Inc. returned +23.7% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Omnicell, Inc. is a healthcare technology company that provides medication management solutions and adherence tools for hospitals, health systems, retail pharmacies, and other care settings.
The most recent item we track (Zacks Investment Research, 13 Oct 2026): "Is This the Right Time to Retain Omnicell Stock in Your Portfolio?". Omnicell raised its 2026 earnings outlook, citing cost discipline and efficiency. Rising memory costs and delayed adoption of Titan XT remain challenges.
Omnicell, Inc. is a healthcare technology company that provides medication management solutions and adherence tools for hospitals, health systems, retail pharmacies, and other care settings. Omnicell’s portfolio includes automated dispensing systems, central pharmacy automation, robotic dispensing, IV compounding, inventory management software, and point-of-care solutions designed to streamline medication workflows and support safer medication handling. The company also offers patient engagement and medication adherence tools through its EnlivenHealth brand, helping pharmacies and providers manage prescriptions, packaging, and communication more efficiently. Omnicell’s products and services are used across inpatient, outpatient, post-acute, and retail environments, where they support clinical teams with automation, analytics, and workflow integration. The company plays a notable role in healthcare operations by helping organizations improve medication management across the care continuum.
CEO Mr. Randall A. Lipps · 3,485 employees · United States · https://www.omnicell.com
